Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson's disease.

MLA

Miyaue, Noriyuki, et al. “Concomitant Use of Magnesium Oxide Significantly Decreases Absorption of Levodopa Preparations in Patients with Parkinson’s Disease.” Clinical Parkinsonism & Related Disorders, vol. 9, Oct. 2023, p. 100227. EBSCOhost, https://doi.org/10.1016/j.prdoa.2023.100227.

APA

Miyaue, N., Yabe, H., & Nagai, M. (2023). Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders, 9, 100227. https://doi.org/10.1016/j.prdoa.2023.100227

Chicago

Miyaue, Noriyuki, Hayato Yabe, and Masahiro Nagai. 2023. “Concomitant Use of Magnesium Oxide Significantly Decreases Absorption of Levodopa Preparations in Patients with Parkinson’s Disease.” Clinical Parkinsonism & Related Disorders 9 (October): 100227. doi:10.1016/j.prdoa.2023.100227.